FEATURED ARTICLES

• PEIpro® Transfection Reagent For Scalable Virus Production

  Explore this transfection reagent's benefits and learn why it is often chosen for virus production runs in most adherent and suspension cell culture systems.

• Successful Scaling Of Suspension-Based Viral Vector Production

  Explore this discussion amongst experts about how to develop robust, scalable, and cost-effective processes that yield high titers of high-quality viral vectors.

• A Right-First-Time Approach To Viral Vector Manufacturing

  Discover how the presented approaches to overcoming current issues limiting the available capacity for viral-vector manufacturing make gene therapies accessible to more patients.

• Efficiency Of A Transfection Reagent In Hard-To-Transfect Stem Cells

  Discover how our transfection reagent demonstrates robust, non-toxic and efficient gene expression delivery in hard-to-transfect primary hMSCs, mESCs and induced pluripotent stem cells.

• Enhanced Non-Viral Gene Delivery To Stem Cells With mRNA Transfection Reagent

  In this study we demonstrate a delivery mechanism that is a simple and ready-to-use transfection reagent that leads to outstanding transfection efficiencies in known to be hard-to-transfect stem cells.

• Commercializing Advanced Therapy Medicinal Products (ATMPs) Manufacturing Processes

  Improving this one aspect of viral vector manufacturing can help enable scalable production of high-quality vectors with acceptable costs and timelines.

• Zoom On The Importance Of Quality For Viral Vector Manufacturing Optimization

  Industry experts offer advice on the use of GMP raw materials for viral vector manufacturing along with the key points of evolution relating to regulatory guidance and requirements for viral vector production.

• Tailor-Made DNA Plasmids For Viral-Vector Manufacturing

  The conventional approach to plasmid DNA design and construction is not amenable to fine-tuning the structure and properties of the molecules. We explore a method for the design and construction of plasmid DNA from scratch.
  
   

• Differences, Challenges And Best Practices For Manufacturing Of Biologics Under GMP Compliance

  A regulatory affairs specialist discusses best practices and challenges  for manufacturing biologics under GMPs and reviews details around the EU’s revision to Annex 1.

• Optimization Of AAV Production For High-Yielding And Scalable GMP Processes

  By leveraging a standardized, scalable platform approach for viral vector manufacturing, including the transient transfection step, timelines can be accelerated to bring next-generation therapies to market.

• Ancillary Material Regulatory Digest For ATMPs

  It’s worth carefully assessing the eligibility of an AM before as early as possible before entering clinical testing as it will result in a significant gain of time and money.

• Fine-Tuning Transient Transfection Conditions Is A Prerequisite For Optimal Upstream AAV Manufacturing

  Read how optimizing the transfection step during upstream process development leverages tremendous benefits on overall costs, robustness and scalability of an AAV production platform.

• Improving Expression And Purification Of mAb

  To achieve high transient protein yields, TGE is dependent on an efficient transfection method. We review a system for optimal protein production in several commercially available suspension CHO cell lines.

• Transfection Toolbox For Spike Protein Vaccine Strategies

  We review 4 main strategies for current COVID-19 vaccines currently in development: virus-based vaccines, nucleic acid-based vaccines, protein-based vaccines and viral vector vaccines.

• Expression Of Recombinant Proteins

  The expression of recombinant proteins has evolved to allow the development of innovative diagnostic and therapeutic applications.

• Viral Vectors For Gene Therapy In A Nutshell: AAVs, Lentivirus, Adenovirus And Retrovirus

  We review the four main types of viral vectors utilized for gene therapy applications and chemical transfection reagents options for efficient production of viral vectors at all scales.

• Transfection Solutions For Highly Reliable And Effective Gene Silencing With siRNA And Co.

  We discuss the process of transfection and highlight two highly effective vectors for both in vitro and in vivo gene therapy applications.

• Lentiviral Transfection For Advancing Cell-Based Gene Therapy

  Explore how lentiviral vectors can be used across a range of clinically relevant cell-based gene therapies and highlight a transfection reagent has become the gold standard for efficient, reproducible and cost-effective lentivirus manufacturing.

• The Importance Of Raw Materials In Viral Vector Manufacturing

  It is extremely important to confirm the identity, purity, and quality of raw materials prior to starting the viral vector manufacturing to ensure patient safety is being considered and safeguarded from the start of the manufacturing process.

• Manufacturing A Gene Therapy With Patient Safety In Mind

  To monitor and guarantee their safety, advanced medicines need to follow strict and specific cGMP regulations, similarly to what applies to standard pharmaceuticals.